Barclays Maintains a Buy Rating on Thermo Fisher (TMO)

By Austin Angelo

Barclays analyst Jack Meehan maintained a Buy rating on Thermo Fisher (TMOResearch Report) today and set a price target of $280. The company’s shares opened today at $218.76.

According to TipRanks.com, Meehan is a 4-star analyst with an average return of 4.2% and a 54.1% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, IQVIA Holdings Inc, and Myriad Genetics.

Currently, the analyst consensus on Thermo Fisher is a Moderate Buy with an average price target of $269.80.

See today’s analyst top recommended stocks >>

The company has a one-year high of $253.91 and a one-year low of $194.51. Currently, Thermo Fisher has an average volume of 1.87M.

Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Services.